Literature DB >> 34547466

Sphingosine-1-phosphate transporter spinster homolog 2 is essential for iron-regulated metastasis of hepatocellular carcinoma.

Min Li1, Yuxiao Tang2, Dongyao Wang3, Xiaofeng Zhai4, Hui Shen2, Chen Zhong5, Man Yao4, Aiguo Jin4, Zhengjun Zhou6, Shaolai Zhou6, Jia Fan6, Chang-Quan Ling7, Chen Ling8.   

Abstract

Iron dyshomeostasis is associated with hepatocellular carcinoma (HCC) development. However, the role of iron in HCC metastasis is unknown. This study aimed to elucidate the underlying mechanisms of iron's enhancement activity on HCC metastasis. In addition to the HCC cell lines and clinical samples in vitro, iron-deficient (ID) mouse models were generated using iron-free diet and transferrin receptor protein knockout, followed by administration of HCC tumors through either orthotopic or ectopic route. Clinical metastatic HCC samples showed significant ID status, accompanied by overexpression of sphingosine-1-phosphate transporter spinster homolog 2 (SPNS2). Mechanistically, ID increased SPNS2 expression, leading to HCC metastasis in both cell cultures and mouse models. ID not only altered the anti-tumor immunity, which was indicated by phenotypes of lymphatic subsets in the liver and lung of tumor-bearing mice, but also promoted HCC metastasis in a cancer cell autonomous manner through the SPNS2. Since germline knockout of globe SPNS2 showed significantly reduced HCC metastasis, we further developed hepatic-targeting recombinant adeno-associated virus vectors to knockdown SPNS2 expression and to inhibit iron-regulated HCC metastasis. Our observation indicates the role of iron in HCC pulmonary metastasis and suggests SPNS2 as a potential therapeutic target for the prevention of HCC pulmonary metastasis.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  adeno-associated viral vectors; hepatocellular carcinoma; iron deficiency; metastasis; sphingosine-1-phosphate transporter spinster homolog 2

Mesh:

Substances:

Year:  2021        PMID: 34547466      PMCID: PMC8821935          DOI: 10.1016/j.ymthe.2021.09.012

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  41 in total

1.  Deferoxamine for advanced hepatocellular carcinoma.

Authors:  Takahiro Yamasaki; Shuji Terai; Isao Sakaida
Journal:  N Engl J Med       Date:  2011-08-11       Impact factor: 91.245

2.  miR-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis.

Authors:  Shao-Lai Zhou; Zhi-Qiang Hu; Zheng-Jun Zhou; Zhi Dai; Zheng Wang; Ya Cao; Jia Fan; Xiao-Wu Huang; Jian Zhou
Journal:  Hepatology       Date:  2016-03-07       Impact factor: 17.425

3.  miR-212 mediates counter-regulation on CRH expression and HPA axis activity in male mice.

Authors:  Yuxiao Tang; Xingjian Cai; Hongwei Zhang; Hui Shen; Wanyin Wang; Zhilei Shen; Wei Gu; Changquan Ling; Min Li
Journal:  J Mol Endocrinol       Date:  2017-09-14       Impact factor: 5.098

4.  Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies.

Authors:  Qian Ba; Miao Hao; He Huang; Junmei Hou; Shichao Ge; Zhuzhen Zhang; Jun Yin; Ruiai Chu; Hualiang Jiang; Fudi Wang; Kaixian Chen; Hong Liu; Hui Wang
Journal:  Clin Cancer Res       Date:  2011-11-03       Impact factor: 12.531

5.  Ferroportin and iron regulation in breast cancer progression and prognosis.

Authors:  Zandra K Pinnix; Lance D Miller; Wei Wang; Ralph D'Agostino; Tim Kute; Mark C Willingham; Heather Hatcher; Lia Tesfay; Guangchao Sui; Xiumin Di; Suzy V Torti; Frank M Torti
Journal:  Sci Transl Med       Date:  2010-08-04       Impact factor: 17.956

6.  A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors.

Authors:  Kabir Mody; Aaron S Mansfield; Lalitha Vemireddy; Peter Nygren; Joachim Gulbo; Mitesh Borad
Journal:  Invest New Drugs       Date:  2018-11-21       Impact factor: 3.850

7.  Prevalence of neutralizing antibodies against liver-tropic adeno-associated virus serotype vectors in 100 healthy Chinese and its potential relation to body constitutions.

Authors:  Chen Ling; Yuan Wang; Ying-lu Feng; Ya-ni Zhang; Jun Li; Xin-rui Hu; Li-na Wang; Mao-feng Zhong; Xiao-feng Zhai; Irene Zolotukhin; Arun Srivastava; Chang-quan Ling
Journal:  J Integr Med       Date:  2015-09

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  Robust enumeration of cell subsets from tissue expression profiles.

Authors:  Aaron M Newman; Chih Long Liu; Michael R Green; Andrew J Gentles; Weiguo Feng; Yue Xu; Chuong D Hoang; Maximilian Diehn; Ash A Alizadeh
Journal:  Nat Methods       Date:  2015-03-30       Impact factor: 28.547

10.  Metastatic growth instructed by neutrophil-derived transferrin.

Authors:  Wei Liang; Qin Li; Napoleone Ferrara
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-09       Impact factor: 11.205

View more
  4 in total

Review 1.  Adeno-associated virus vector-mediated gene therapy for the treatment of ovarian cancer: a literature review.

Authors:  Jiaojiao Zhu; Tiansheng Qin; Linzhen Wei; Fan Chen; Yaoyao Ding; Qianqian Zhang; Yamei Dang
Journal:  Ann Transl Med       Date:  2022-09

2.  Antitumor Effect of Pseudolaric Acid B Involving Regulation of Notch1/Akt Signaling Response in Human Hepatoma Cell In Vitro.

Authors:  Haijun Gao; Yan Zhang; Xiaojin Mo; Lele Huo; Yanping Luo; Ting Zhang; Xingming Ma; Wei Hu; Tao Jing
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-14       Impact factor: 2.650

Review 3.  Keep a Little Fire Burning-The Delicate Balance of Targeting Sphingosine-1-Phosphate in Cancer Immunity.

Authors:  Catherine Olesch; Bernhard Brüne; Andreas Weigert
Journal:  Int J Mol Sci       Date:  2022-01-24       Impact factor: 5.923

4.  Loss of SLC46A1 decreases tumor iron content in hepatocellular carcinoma.

Authors:  Dongyao Wang; Huiwen Wu; Jianxin Yang; Min Li; Changquan Ling; Zelong Gao; Hongtao Lu; Hui Shen; Yuxiao Tang
Journal:  Hepatol Commun       Date:  2022-07-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.